Lead Product(s) : Paroxetine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Concentration-QT Study of Paroxetine in Healthy Adults
Details : Paroxetine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Anxiety Disorders.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 04, 2023
Lead Product(s) : Paroxetine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Paroxetine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase IV
Sponsor : Patient-Centered Outcomes Research Institute | Corporal Michael J. Crescenz VA Medical Center | Coatesville VA Medical Center | Milwaukee VA Medical Center | North Texas Veterans Healthcare System | San Diego Veterans Healthcare System | VA Palo Alto Heal
Deal Size : Inapplicable
Deal Type : Inapplicable
A Comparison of Prolonged Exposure Therapy, Pharmacotherapy, and Their Combination for PTSD
Details : Paroxetine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Stress Disorders, Post-Traumatic.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 14, 2021
Lead Product(s) : Paroxetine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase IV
Sponsor : Patient-Centered Outcomes Research Institute | Corporal Michael J. Crescenz VA Medical Center | Coatesville VA Medical Center | Milwaukee VA Medical Center | North Texas Veterans Healthcare System | San Diego Veterans Healthcare System | VA Palo Alto Heal
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Paroxetine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Paroxetine HCl is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Anxiety Disorders.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 17, 2020
Lead Product(s) : Paroxetine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Paroxetine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : Beijing Winsunny Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Paroxetine HCl is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Depressive Disorder, Major.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 20, 2018
Lead Product(s) : Paroxetine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : Beijing Winsunny Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Paroxetine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Paroxetine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Anxiety Disorders.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 06, 2017
Lead Product(s) : Paroxetine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Paroxetine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase IV
Sponsor : Max-Planck-Institute Psychiatry
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Paroxetine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Depressive Disorder, Major.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 12, 2014
Lead Product(s) : Paroxetine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase IV
Sponsor : Max-Planck-Institute Psychiatry
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Paroxetine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Paroxetine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Depressive Disorder.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 05, 2013
Lead Product(s) : Paroxetine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Paroxetine Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Johnson & Johnson Innovative Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable
Interaction Between Paroxetine and Telaprevir
Details : Paroxetine is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Hepatitis C.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 26, 2013
Lead Product(s) : Paroxetine Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Johnson & Johnson Innovative Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Paroxetine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Paxil CR Bioequivalence Study Brazil - Fed Administration
Details : Paroxetine HCl is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Depressive Disorder.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 20, 2011
Lead Product(s) : Paroxetine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
